Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress

被引：0
|
作者：
Oh, Do-Youn
Kim, Jin Won
Chon, Hongjae
Lee, Choong-Kun
Kim, Ji-Won
Kang, Beodeul
Choi, Hye Jin
Park, Se Jun
Yoon, Jeesun
Lee, Myung Ah
机构：
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Canc Res Inst,Coll Med, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[3] CHA Univ, CHA Bundang Med Ctr, Med Oncol, Seongnam, South Korea
[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Internal Med,Div Med Oncol, Seoul, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Coll Med, Seongnam, South Korea
[6] Yonsei Univ, Dept Internal Med, Yonsei Canc Ctr, Coll Med,Div Med Oncol, Seoul, South Korea
[7] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Coll Med,Div Oncol, Seoul, South Korea
[8] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS490
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS490
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for Stage IIIB/IV disease.
    Govindan, R
    Crowley, J
    Schwartzberg, L
    Kennedy, P
    Ekstrand, BC
    Sandler, A
    Jaunakais, D
    Ghalie, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
  • [22] Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer
    Penz, M
    Kornek, GV
    Raderer, M
    Ulrich-Pur, H
    Fiebiger, W
    Lenauer, A
    Depisch, D
    Krauss, G
    Schneeweiss, B
    Scheithauer, W
    ANNALS OF ONCOLOGY, 2001, 12 (02) : 183 - 186
  • [23] BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy
    O'Kane, G. M.
    Spratlin, J.
    Oh, D-Y.
    Rha, S. Y.
    McWhirter, E.
    Elimova, E.
    Kavan, P.
    Choi, M. K.
    Kim, D.
    Goodwin, R. A.
    Hecht, J. R.
    Koo, D-H.
    Halani, K.
    McAllister, R.
    Jones, M.
    Snow, M. D.
    Lemmerick, Y.
    Spera, G.
    Pankovich, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S22 - S22
  • [24] Prospective Phase II Trial of Gemcitabine in Combination with Irinotecan as First-Line Chemotherapy in Patients with Advanced Biliary Tract Cancer
    Chung, Moon Jae
    Kim, Yoon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Song, Si Young
    Chung, Jae Bock
    Park, Seung Woo
    CHEMOTHERAPY, 2011, 57 (03) : 236 - 243
  • [25] A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
    Chiang, N-J.
    Bai, L-Y.
    Huang, C-J.
    Chen, S-C.
    Hsiao, C-F.
    Shan, Y-S.
    Su, Y-Y.
    Chen, L.
    Chen, M-H.
    ANNALS OF ONCOLOGY, 2021, 32 : S377 - S377
  • [26] A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
    Kanai, Masashi
    Yoshimura, Kenichi
    Tsumura, Takehiko
    Asada, Masanori
    Suzuki, Chihiro
    Niimi, Miyuki
    Matsumoto, Shigemi
    Nishimura, Takafumi
    Nitta, Takashi
    Yasuchika, Kentaro
    Taura, Kojiro
    Mori, Yukiko
    Hamada, Akihiko
    Inoue, Naoya
    Tada, Shinsuke
    Yanagihara, Kazuhiro
    Yazumi, Shujiro
    Osaki, Yukio
    Chiba, Tsutomu
    Ikai, Iwao
    Fukushima, Masanori
    Uemoto, Shinji
    Hatano, Etsuro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1429 - 1434
  • [27] A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
    Masashi Kanai
    Kenichi Yoshimura
    Takehiko Tsumura
    Masanori Asada
    Chihiro Suzuki
    Miyuki Niimi
    Shigemi Matsumoto
    Takafumi Nishimura
    Takashi Nitta
    Kentaro Yasuchika
    Kojiro Taura
    Yukiko Mori
    Akihiko Hamada
    Naoya Inoue
    Shinsuke Tada
    Kazuhiro Yanagihara
    Shujiro Yazumi
    Yukio Osaki
    Tsutomu Chiba
    Iwao Ikai
    Masanori Fukushima
    Shinji Uemoto
    Etsuro Hatano
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1429 - 1434
  • [28] Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer
    Watanabe, Akinori
    Kida, Mitsuhiro
    Miyazawa, Shiro
    Iwai, Tomohisa
    Okuwaki, Kosuke
    Kaneko, Toru
    Yamauchi, Hiroshi
    Takezawa, Miyoko
    Imaizumi, Hiroshi
    Koizumi, Wasaburo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (19) : 5979 - 5984
  • [29] Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study
    Lee, Yong-Pyo
    Oh, Sung Yong
    Kim, Kwang Min
    Go, Se-Il
    Kim, Jung Hoon
    Huh, Seok Jae
    Kang, Jung Hun
    Ji, Jun Ho
    CANCERS, 2022, 14 (08)
  • [30] 5,10 methylenetetrahydrofolic acid with fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase II study
    Stewart, J.
    Berman, G.
    Semiglazov, V. F.
    Gomez, H. L.
    De La Cruz Vargas, A.
    Falcon, S.
    Akhmadullina, L. I.
    Guerrero, A.
    Varela, M.
    Martin, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345